INTRODUCTION

Frontotemporal Dementia
Introduction
Murray Grossman, MD, EdD (Alzheimer Dis Assoc Disord 2005; 19 :S1-S2) F rontotemporal dementia (FTD) is a progressive neurodegenerative condition with two major forms of presentation: a progressive form of aphasia, and a disorder of social comportment and personality. Epidemiologic studies suggest that FTD is as common as Alzheimer disease (AD) among individuals less than 65 years of age, representing up to 15% of patients with a dementia. FTD thus is an important condition because of its incidence in younger individuals who are in the work force and have primary family roles and responsibilities. Autopsy studies indicate that FTD is caused by many different histopathologic conditions. Although FTD may be caused by processes that are free of soluble tau such as frontotemporal lobar degeneration with ubiquitin inclusions (FTLD-U) and dementia lacking distinctive histopathology (DLDH), the underlying etiology often is a primary tauopathy such as Pick's disease or corticobasal degeneration. The neurobiology of FTD is important to understand because the abnormal accumulation of tau has become an important therapeutic target in many neurodegenerative diseases, including many common conditions like AD.
The papers contributing to this special issue are representative of the presentations at a two-day meeting of internationally recognized experts, The Frontotemporal Dementia Satellite Meeting, held at the University of Pennsylvania in Philadelphia on July [15] [16] 2004 , just before the 9th International Conference on Alzheimer's Disease, which was sponsored by the Alzheimer's Association and also held in Philadelphia. The sessions covered four issues critical to understanding FTD: clinical and neuropsychological studies of FTD, investigative biomarkers of FTD, genetic studies of FTD, and neuropathologic models of FTD.
Clinical diagnosis of FTD remains controversial because of the varied clinical presentation. Some argue that there is considerable overlap between FTD and other neurodegenerative conditions, and that the various phenotypes identified as FTD represent different stages of this disease process. Other investigators claim that recognition of distinctive features within the spectrum of progressive aphasia and social disorder can contribute importantly to the accurate diagnosis of FTD. In this issue, Knibbs and Hodges argue that semantic dementia has a unique clinical presentation involving a disorder of conceptual knowledge that is separate from the language deficit of primary progressive aphasia. Passant describes the distinctive characteristics of the social and personality disorder that are seen in FTD. Kertesz argues, on the other hand, that there is considerable overlap between these phenotypes because various combinations of these clinical presentations can emerge in a single patient.
In the context of this debate, some clinical investigators have begun to develop biomarkers that can refine the clinical diagnosis of FTD. These biomarkers also can be used to reflect disease response in treatment trials. Many proteins thus have been examined in the cerebrospinal fluid of FTD patients to identify a specific profile that distinguishes FTD from AD. Increasingly sophisticated neuroimaging techniques have been developed as well, and these have been validated by correlation with empirical clinical observations and through longitudinal investigation. More recently, approaches have been developed that allow direct imaging of abnormally accumulating proteins in the brains of patients suffering from a neurodegenerative disease. In this issue, Boxer and Miller use magnetic resonance imaging (MRI) to associate each of the three major clinical phenotypes of FTD with a distinct anatomic distribution of cortical atrophy. Avants and co-workers introduce a novel technique for monitoring the longitudinal decline of FTD with highresolution MRI studies, and correlate their imaging observations to the progressive cognitive breakdown seen in FTD.
Mutations of the microtubule-associated-protein-tau (MAPT) gene on chromosome 17 are recognized to cause FTD in about 6% to 7% of patients. Yet other families have been identified with strong evidence for an autosomal dominant inheritance pattern but without an identified mutation in MAPT. Gene discovery investigations are being conducted to identify other disease-associated genetic loci as well as syndromes where FTD contributes to the clinical presentation. Moreover, novel mechanisms are being investigated that may contribute to the emergence of FTD, such as abnormalities in the processing of tau. In this issue, Kimonis and Watts describe an autosomal dominant inclusion body myopathy associated with Paget disease and FTD that maps to chromosome 9 and involves a mutation of the valosin containing protein (VCP) gene. Studies of VCP functioning provide new insights into the etiology of FTD. Kar, Wu, and colleagues review the mechanisms involved in tau processing, focusing on abnormalities of tau splicing regulation.
Neuropathologic models of tau are crucial because of the insight they provide into the mechanisms of disease. Whereas it is often assumed that a disorder of tau manifests itself in cortical degeneration, the specific nature of the tauopathy may vary depending on the particular tau mutation underlying the disorder. Indeed, it now appears that glial pathology contributes to FTD as well. These neuropathologic models are important to understand because they will also play a crucial role in the development of treatments. In this issue, Katsuse and Dickson discuss the tau-negative spectrum of conditions presenting with FTD. Comparing the anatomic distribution and immunoreactive properties of ubiquitin, these investigators conclude that FTD cases with and without motor neuron disease have a different pathogenesis.
Whereas the field of FTD is generally not as mature as AD, studies of FTD are progressing very rapidly because of the cross-disciplinary, hypothesis-driven nature of the research. This spirit was well represented at the Philadelphia meeting.
Another important feature of the meeting included the participation of FTD families and caregivers. These patients and families face many difficult and unique medical, social, and emotional challenges. This meeting provided a forum for physicians, researchers, and families for mutual education and discussion of critical issues. The Association for Frontotemporal Dementias (AFTD) was pleased to make the arrangements for caregivers during the FTD Symposium.
This meeting would not have occurred without the extraordinary efforts of the Program Committee, including Virginia M. Y. Lee, Bruce Miller, John van Swieten, John Q. Trojanowski, and Murray Grossman. Gayle Viale Joseph and Jennifer Farmer were instrumental in implementing the meeting, and the meeting would not have been possible without their incredibly hard work. Additional support for the meeting came from the National Institute of Aging and the National Institute of Neurologic Disorders and Stroke of the National Institutes of Health, the Institute on Aging of the University of Pennsylvania, the Association for Frontotemporal Dementias, the William Maul Measey-Truman G. Schnabel Foundation, the Oxford Foundation, Forest Laboratories, Janssen Pharmaceutica, Merck & Company Incorporated, Pfizer Incorporated, and most importantly, from the friends and families of patients with frontotemporal dementia who make our research possible.
